These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

268 related articles for article (PubMed ID: 20713596)

  • 81. Antibody to E1 peptide of hepatitis C virus genotype 4 inhibits virus binding and entry to HepG2 cells in vitro.
    El-Awady MK; Tabll AA; Atef K; Yousef SS; Omran MH; El-Abd Y; Bader-Eldin NG; Salem AM; Zohny SF; El-Garf WT
    World J Gastroenterol; 2006 Apr; 12(16):2530-5. PubMed ID: 16688798
    [TBL] [Abstract][Full Text] [Related]  

  • 82. HCV infection of the transplanted liver: changing CD81 and HVR1 variants immediately after liver transplantation.
    Hughes MG; Chong TW; Smith RL; Evans HL; Iezzoni JC; Sawyer RG; Rudy CK; Pruett TL
    Am J Transplant; 2005 Oct; 5(10):2504-13. PubMed ID: 16162201
    [TBL] [Abstract][Full Text] [Related]  

  • 83. Griffithsin has antiviral activity against hepatitis C virus.
    Meuleman P; Albecka A; Belouzard S; Vercauteren K; Verhoye L; Wychowski C; Leroux-Roels G; Palmer KE; Dubuisson J
    Antimicrob Agents Chemother; 2011 Nov; 55(11):5159-67. PubMed ID: 21896910
    [TBL] [Abstract][Full Text] [Related]  

  • 84. Entry Inhibitors of Hepatitis C Virus.
    Qian XJ; Qi ZT
    Adv Exp Med Biol; 2022; 1366():207-222. PubMed ID: 35412143
    [TBL] [Abstract][Full Text] [Related]  

  • 85. Recombinant human L-ficolin directly neutralizes hepatitis C virus entry.
    Hamed MR; Brown RJ; Zothner C; Urbanowicz RA; Mason CP; Krarup A; McClure CP; Irving WL; Ball JK; Harris M; Hickling TP; Tarr AW
    J Innate Immun; 2014; 6(5):676-84. PubMed ID: 24854201
    [TBL] [Abstract][Full Text] [Related]  

  • 86. Characterization of the cross-neutralizing antibody response against hepatitis C virus in the liver transplantation setting.
    Dragun J; Pérez-Del-Pulgar S; Crespo G; Ramírez S; Coto-Llerena M; Mensa L; García-Valdecasas JC; Navasa M; Forns X
    Am J Transplant; 2011 Apr; 11(4):767-74. PubMed ID: 21401864
    [TBL] [Abstract][Full Text] [Related]  

  • 87. Quasispecies dynamics in hepatitis C liver transplant recipients receiving grafts from hepatitis C virus infected donors.
    Pérez-Del-Pulgar S; Gregori J; Rodríguez-Frías F; González P; García-Cehic D; Ramírez S; Casillas R; Domingo E; Esteban JI; Forns X; Quer J
    J Gen Virol; 2015 Dec; 96(12):3493-3498. PubMed ID: 26395289
    [TBL] [Abstract][Full Text] [Related]  

  • 88. Hepatitis C virus receptors claudin-1 and occludin after liver transplantation and influence on early viral kinetics.
    Mensa L; Crespo G; Gastinger MJ; Kabat J; Pérez-del-Pulgar S; Miquel R; Emerson SU; Purcell RH; Forns X
    Hepatology; 2011 May; 53(5):1436-45. PubMed ID: 21294144
    [TBL] [Abstract][Full Text] [Related]  

  • 89. Human monoclonal antibody MBL-HCV1 delays HCV viral rebound following liver transplantation: a randomized controlled study.
    Chung RT; Gordon FD; Curry MP; Schiano TD; Emre S; Corey K; Markmann JF; Hertl M; Pomposelli JJ; Pomfret EA; Florman S; Schilsky M; Broering TJ; Finberg RW; Szabo G; Zamore PD; Khettry U; Babcock GJ; Ambrosino DM; Leav B; Leney M; Smith HL; Molrine DC
    Am J Transplant; 2013 Apr; 13(4):1047-1054. PubMed ID: 23356386
    [TBL] [Abstract][Full Text] [Related]  

  • 90. Rapid induction of virus-neutralizing antibodies and viral clearance in a single-source outbreak of hepatitis C.
    Pestka JM; Zeisel MB; Bläser E; Schürmann P; Bartosch B; Cosset FL; Patel AH; Meisel H; Baumert J; Viazov S; Rispeter K; Blum HE; Roggendorf M; Baumert TF
    Proc Natl Acad Sci U S A; 2007 Apr; 104(14):6025-30. PubMed ID: 17392433
    [TBL] [Abstract][Full Text] [Related]  

  • 91. Safety and Efficacy of Avaren-Fc Lectibody Targeting HCV High-Mannose Glycans in a Human Liver Chimeric Mouse Model.
    Dent M; Hamorsky K; Vausselin T; Dubuisson J; Miyata Y; Morikawa Y; Matoba N
    Cell Mol Gastroenterol Hepatol; 2021; 11(1):185-198. PubMed ID: 32861832
    [TBL] [Abstract][Full Text] [Related]  

  • 92. Humanisation of a claudin-1-specific monoclonal antibody for clinical prevention and cure of HCV infection without escape.
    Colpitts CC; Tawar RG; Mailly L; Thumann C; Heydmann L; Durand SC; Xiao F; Robinet E; Pessaux P; Zeisel MB; Baumert TF
    Gut; 2018 Apr; 67(4):736-745. PubMed ID: 28360099
    [TBL] [Abstract][Full Text] [Related]  

  • 93. Inducing Hepatitis C Virus Resistance After Pig Liver Transplantation-A Proof of Concept of Liver Graft Modification Using Warm Ex Vivo Perfusion.
    Goldaracena N; Spetzler VN; Echeverri J; Kaths JM; Cherepanov V; Persson R; Hodges MR; Janssen HL; Selzner N; Grant DR; Feld JJ; Selzner M
    Am J Transplant; 2017 Apr; 17(4):970-978. PubMed ID: 27805315
    [TBL] [Abstract][Full Text] [Related]  

  • 94. Entry Inhibitors: A Perspective for Prevention of Hepatitis C Virus Infection in Organ Transplantation.
    Colpitts CC; Chung RT; Baumert TF
    ACS Infect Dis; 2017 Sep; 3(9):620-623. PubMed ID: 28812869
    [TBL] [Abstract][Full Text] [Related]  

  • 95. Persistent hepatitis C virus infection in vitro: coevolution of virus and host.
    Zhong J; Gastaminza P; Chung J; Stamataki Z; Isogawa M; Cheng G; McKeating JA; Chisari FV
    J Virol; 2006 Nov; 80(22):11082-93. PubMed ID: 16956932
    [TBL] [Abstract][Full Text] [Related]  

  • 96. Clearance of persistent hepatitis C virus infection in humanized mice using a claudin-1-targeting monoclonal antibody.
    Mailly L; Xiao F; Lupberger J; Wilson GK; Aubert P; Duong FHT; Calabrese D; Leboeuf C; Fofana I; Thumann C; Bandiera S; Lütgehetmann M; Volz T; Davis C; Harris HJ; Mee CJ; Girardi E; Chane-Woon-Ming B; Ericsson M; Fletcher N; Bartenschlager R; Pessaux P; Vercauteren K; Meuleman P; Villa P; Kaderali L; Pfeffer S; Heim MH; Neunlist M; Zeisel MB; Dandri M; McKeating JA; Robinet E; Baumert TF
    Nat Biotechnol; 2015 May; 33(5):549-554. PubMed ID: 25798937
    [TBL] [Abstract][Full Text] [Related]  

  • 97. Neutralization and receptor use of infectious culture-derived rat hepacivirus as a model for HCV.
    Wolfisberg R; Thorselius CE; Salinas E; Elrod E; Trivedi S; Nielsen L; Fahnøe U; Kapoor A; Grakoui A; Rice CM; Bukh J; Holmbeck K; Scheel TKH
    Hepatology; 2022 Nov; 76(5):1506-1519. PubMed ID: 35445423
    [TBL] [Abstract][Full Text] [Related]  

  • 98. Hepatitis C virus envelope glycoprotein fitness defines virus population composition following transmission to a new host.
    Brown RJ; Hudson N; Wilson G; Rehman SU; Jabbari S; Hu K; Tarr AW; Borrow P; Joyce M; Lewis J; Zhu LF; Law M; Kneteman N; Tyrrell DL; McKeating JA; Ball JK
    J Virol; 2012 Nov; 86(22):11956-66. PubMed ID: 22855498
    [TBL] [Abstract][Full Text] [Related]  

  • 99. Modeling hepatitis C virus kinetics during liver transplantation reveals the role of the liver in virus clearance.
    Shekhtman L; Navasa M; Sansone N; Crespo G; Subramanya G; Chung TL; Cardozo-Ojeda EF; Pérez-Del-Pulgar S; Perelson AS; Cotler SJ; Forns X; Uprichard SL; Dahari H
    Elife; 2021 Nov; 10():. PubMed ID: 34730511
    [TBL] [Abstract][Full Text] [Related]  

  • 100. Early, rapidly progressive cholestatic hepatitis C reinfection and graft loss after adult living donor liver transplantation.
    Troppmann C; Rossaro L; Perez RV; McVicar JP
    Am J Transplant; 2003 Feb; 3(2):239-40. PubMed ID: 12603221
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.